Open AccessImpact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
Author(s) -
Giovanna Li Petri,
Btissame El Hassouni,
Rocco Sciarrillo,
Niccola Funel,
G. Mantini,
Eveline A. Zeeuw van der Laan,
Stella Cascioferro,
Amir Avan,
Paolo Andrea Zucali,
Nadia Zaffaroni,
Tonny Lagerweij,
Barbara Parrino,
Kees Smid,
Marcello Deraco,
Tiziano Tuccinardi,
Alicja Braczko,
Ryszard T. Smoleński,
Larry H. Matherly,
Gerrit Jansen,
Yehuda G. Assaraf,
Patrizia Diana,
Jacqueline Cloos,
Godefridus J. Peters,
Filippo Minutolo,
Elisa Giovannetti
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0912-9
Subject(s) - pemetrexed , mesothelioma , cancer research , gene silencing , hypoxia (environmental) , lactate dehydrogenase , gemcitabine , in vivo , biology , pathology , microbiology and biotechnology , chemistry , medicine , chemotherapy , cisplatin , enzyme , gene , biochemistry , organic chemistry , oxygen
Expression of proton-coupled folate transporter (PCFT) is associated with survival of mesothelioma patients treated with pemetrexed, and is reduced by hypoxia, prompting studies to elucidate their correlation.